FDA signals Clene’s ALS therapy may qualify for accelerated approval pathway supported by biomarker-based evidence.
A small regulatory sentence that could carry outsized weight for ALS patients waiting for the time they don’t have. In biotech, the most important developments can arrive in the form of carefully worded regulatory language. That seems to be the case for Clene Inc, which has received final meeting minutes from the US Food and Drug Administration (FDA) indicating that its ALS program may qualify for an accelerated approval submission, a pathway designed for serious diseases where traditional timelines are simply too slow [1].
The FDA stated that Clene’s “proposed data may be capable of supporting the submission and review of a New Drug Application (NDA) under the accelerated approval pathway for the treatment of ALS.”
It’s neither an approval nor a filing yet. However, in the world of neurodegeneration, where decades can pass without meaningful therapeutic progress, it is a meaningful opening.
ALS (amyotrophic lateral sclerosis) is one of those diseases that forces regulators, scientists and clinicians to rethink what “proof” should look like. Waiting for long-term survival data is often like trying to measure the outcome of a storm after the house has already collapsed. The disease progresses quickly, unpredictably and with devastating consequences. That’s where biomarkers enter the conversation.
In Clene’s case, the focus is neurofilament light (NfL), a protein released when nerve cells are damaged. Think of it as a kind of biological “stress signal” – the higher it rises, the more active the neurodegeneration.
The FDA acknowledged this potential shift in thinking, noting that “NfL could potentially serve as a reasonably likely surrogate endpoint to support (an) accelerated approval.”
In simpler terms, instead of waiting years to confirm whether patients live longer, regulators may consider whether changes in a blood marker reliably reflect disease slowing. It’s an important change from outcomes that take years to observe to signals that may emerge within months.
Clene now expects to submit its NDA for CNM-Au8 in the third quarter of 2026, under the FDA’s Subpart H accelerated approval pathway.
CNM-Au8 itself is an investigational therapy that targets cellular energy systems in the nervous system. The idea is not to “fix” ALS in one stroke, but to support the survival and function of neurons under stress – almost like reinforcing the energy supply of a system that is slowly running out of fuel.
The planned submission will be supported by data from multiple studies, including the Phase 2 HEALEY ALS Platform Trial, the RESCUE-ALS trial, and an NIH-sponsored expanded access program.
Across these datasets, Clene has reported reductions in plasma NfL that were associated with longer survival signals in open-label extension data, though, importantly, these remain exploratory findings in a complex disease landscape.
The FDA has also asked the company to further strengthen the link between biomarker changes and real clinical benefit – essentially asking: does a lower NfL level truly translate into meaningful patient outcomes?
Clene leadership has framed the FDA interaction as both constructive and pivotal.
“We are encouraged by the FDA’s careful evaluation of the benefits and risks associated with Clene’s ALS drug candidate, CNM-Au8,” said Rob Etherington, President and CEO of Clene. “The filing of an NDA submission represents an important milestone for CNM-Au8 and for the ALS community.”
There’s a careful tone here, and for good reason. Accelerated approval is not a shortcut; it is a conditional bet. The therapy still needs to demonstrate confirmatory clinical benefit after approval or risk being reconsidered.
Sandra Abrevaya, Co-Founder of I AM ALS, emphasized the immediate need for action by stating that individuals living with the condition do not have the luxury of time. She explained that adopting flexible, science-based regulatory strategies is essential to accelerating access to new treatments for a rapidly progressing, fatal disease.
What’s quietly unfolding here is bigger than CNM-Au8 alone. The FDA’s willingness to engage with NfL as a “reasonably likely surrogate endpoint” signals a broader shift in neurodegenerative drug development. If biomarkers like NfL become more widely accepted, future ALS trials (and potentially other diseases like Parkinson’s or multiple sclerosis) could move faster from hypothesis to treatment. That doesn’t remove uncertainty; it compresses it. In medicine, compression of time is often as valuable as certainty itself.
Zooming out, this story sits squarely in a larger longevity question: how do we preserve function, not just extend life?
ALS is one of the most extreme breakdowns of biological resilience, where the nervous system loses its ability to sustain itself. Therapies like CNM-Au8 are attempting to intervene not after failure, but during decline, a shift that aligns closely with the broader longevity movement.
If biomarkers like NfL continue to gain regulatory trust, we may be witnessing a structural change in how medicine approaches aging-related degeneration: less waiting for irreversible outcomes and more reading the early signals of biological stress.
